Payment overview · 2025
General Payments
$264.86
6 reported records · 4 companies
Healthcare provider profile · identity verified
Dannie E Williams, MD
Allopathic & Osteopathic Physicians|Family Medicine · OVERLAND, MO · NPI 1568626349
Verified facts
What the public records show
CMS Open Payments records show Dannie E Williams, MD received $264.86 in general payments during 2025 across 6 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 54.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Vraylar by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $145.41 | 54.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $41.10 | 15.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $39.81 | 15.0% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $38.54 | 14.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $226.32 | 5 |
| Education | $38.54 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $145.41 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $41.10 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $39.81 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $39.81 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $38.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
45 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 452 | 154 |
| Atorvastatin Calcium | Atorvastatin Calcium | 281 | 125 |
| Losartan Potassium | Losartan Potassium | 258 | 98 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 198 | 72 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 198 | 77 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 167 | 69 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 166 | 57 |
| Carvedilol | Carvedilol | 156 | 54 |
| Diclofenac Sodium | Diclofenac Sodium | 147 | 52 |
| Furosemide | Furosemide | 146 | 54 |
| Gabapentin | Gabapentin | 146 | 49 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 138 | 30 |
| Tramadol Hcl | Tramadol Hcl | 135 | 43 |
| Tizanidine Hcl | Tizanidine Hcl | 133 | 39 |
| Omeprazole | Omeprazole | 126 | 43 |
| Ibuprofen | Ibuprofen | 121 | 43 |
| Ozempic | Semaglutide | 114 | 32 |
| Metformin Hcl | Metformin Hcl | 113 | 49 |
| Fluticasone Propionate | Fluticasone Propionate | 106 | 47 |
| Pregabalin | Pregabalin | 106 | 30 |
| Oxycodone Hcl | Oxycodone Hcl | 100 | suppressed |
| Mounjaro | Tirzepatide | 96 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 95 | 45 |
| Levothyroxine Sodium | Levothyroxine Sodium | 90 | 34 |
| Trulicity | Dulaglutide | 84 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 81 | 37 |
| Montelukast Sodium | Montelukast Sodium | 80 | 31 |
| Bupropion Xl | Bupropion Hcl | 79 | 32 |
| Buspirone Hcl | Buspirone Hcl | 72 | 21 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 69 | 54 |
| Celecoxib | Celecoxib | 68 | 24 |
| Potassium Chloride | Potassium Chloride | 67 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 65 | 31 |
| Alprazolam | Alprazolam | 63 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 63 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 63 | 22 |
| Mirtazapine | Mirtazapine | 61 | 21 |
| Famotidine | Famotidine | 60 | 18 |
| Clonidine Hcl | Clonidine Hcl | 59 | 20 |
| Diazepam | Diazepam | 59 | 12 |
| Pentoxifylline | Pentoxifylline | 58 | 12 |
| Trazodone Hcl | Trazodone Hcl | 58 | 24 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 56 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 54 | 17 |
| Memantine Hcl | Memantine Hcl | 54 | 19 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 53 | 24 |
| Azithromycin | Azithromycin | 52 | 43 |
| Jardiance | Empagliflozin | 52 | 15 |
| Prednisone | Prednisone | 51 | 36 |
| Symbicort | Budesonide/Formoterol Fumarate | 51 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 51 | 22 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 50 | 49 |
| Lisinopril | Lisinopril | 50 | 27 |
| Eliquis | Apixaban | 47 | 17 |
| Finasteride | Finasteride | 47 | 19 |
| Alendronate Sodium | Alendronate Sodium | 45 | 18 |
| Linzess | Linaclotide | 45 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 42 | 11 |
| Rexulti | Brexpiprazole | 41 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 41 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 39 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | 14 |
| Sertraline Hcl | Sertraline Hcl | 37 | 13 |
| Zenpep | Lipase/Protease/Amylase | 37 | suppressed |
| Entresto | Sacubitril/Valsartan | 36 | suppressed |
| Oxycontin | Oxycodone Hcl | 35 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 35 | 17 |
| Estradiol | Estradiol | 34 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 34 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | 11 |
| Fluconazole | Fluconazole | 32 | 25 |
| Nitroglycerin | Nitroglycerin | 30 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 29 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | suppressed |
| Naproxen | Naproxen | 29 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 29 | 12 |
| Spironolactone | Spironolactone | 29 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 28 | suppressed |
| Mupirocin | Mupirocin | 28 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Allopurinol | Allopurinol | 26 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 20 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 26 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 25 | suppressed |
| Myrbetriq | Mirabegron | 25 | 12 |
| Nystatin | Nystatin | 25 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Hysingla Er | Hydrocodone Bitartrate | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | 13 |
| Lidocaine | Lidocaine | 23 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 23 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 22 | 11 |
| Ketoconazole | Ketoconazole | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Meloxicam | Meloxicam | 21 | 11 |
| Naltrexone Hcl | Naltrexone Hcl | 21 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Vraylar | Cariprazine Hcl | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | 14 |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | 13 |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 14 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 14 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Xtampza Er | Oxycodone Myristate | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Simvastatin | Simvastatin | 13 | suppressed |
| Ubrelvy | Ubrogepant | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $264.86 · 6 records | Bayer Healthcare Pharmaceuticals Inc. | Cologuard Collection Kit, Kerendia, QULIPTA, REXULTI, UBRELVY | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error